Feb 132013
 

public citizen logo longPlease find links to new tables by Burcu Kilic at Public Citizen’s Global Access to Medicine Program that compare patent linkage and data exclusivity provisions in U.S. Free Trade Agreements and the U.S. proposal to the Trans Pacific Partnership Agreement:

 

FacebookTwitterRedditStumbleUponWordPressTumblrBlogger PostEmailPrintFriendly
Nov 212012
 

Photo: Public Citizen

[Reposted with permission from citizen.org] November 10, 2012 marked the first anniversary of the global Kaletra campaign, a campaign comprising health groups in 12 countries challenging pharmaceutical monopolies including Abbott Laboratories’ hold on HIV/AIDS treatment Kaletra and its components lopinavir and ritonavir. These groups have taken actions through compulsory license requests, patent oppositions, litigation and public campaigning to promote generic competition and lower costs. Several new significant victories have been achieved.  For example, Indonesia issued licenses for seven medicines treating hepatitis B and HIV (including lopinavir+ritonavir). Ecuador issued a second compulsory license for an ARV treatment. A Colombian appellate court ruled that the Ministry of Health violated collective rights to health by failing to require Abbott to comply with the reference price for Kaletra (the Ministry has since imposed this requirement, reducing Kaletra prices by 70%) and must maintain Kaletra on a parallel imports list.  Read below a summary of the actions in each country — and join us! Continue reading »

FacebookTwitterRedditStumbleUponWordPressTumblrBlogger PostEmailPrintFriendly